Linda Stein Gold, MD, discusses an article published in the Journal of Drugs in Dermatology titled, “Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.”
Andrew Blauvelt, MD, MBA, a dermatologist at the Oregon Medical Research Center in Portland, Oregon, discusses the impact Ruxolitinib cream has on itch in patients with atopic dermatitis which has been a predominant issue in disease symptoms....